Assessment of therapeutic biomarkers in the treatment of children with postural tachycardia syndrome and vasovagal syncope. (28th April 2014)

• Record Type: Journal Article
• Authors: Lin, Jing; Jin, Hongfang; Du, Junbao
• Is Part Of: Cardiology in the young. Volume 24:Number 5(2014:Oct.)
• Page Start: 792
• Page End: 796
• Publication Date: 2014-04-28
• Subjects: Pediatric cardiology -- Periodicals; 618.9212
• DOI: 10.1017/S1047951114000316
• Languages: English
• ISSNs: 1047-9511

Abstract

<abstract abstract-type="normal"> <title>Abstract</title> <p> <italic>Background:</italic> Postural tachycardia syndrome and vasovagal syncope are common causes of orthostatic intolerance in children. The supplementation with water, or salt, or midodrine, or β-blocker was applied to children with postural tachycardia syndrome or vasovagal syncope. However, the efficacy of such medication varied and was not satisfied. This review aimed to summarise the current biomarkers in the treatment of the diseases. <italic>Data sources:</italic> Studies were collected from online electronic databases, including OVID Medline, PubMed, ISI Web of Science, and associated references. The main areas assessed in the included studies were clinical improvement, the cure rate, and the individualised treatment for postural tachycardia syndrome and vasovagal syncope in children. <italic>Results:</italic> Haemodynamic change during head-up tilt test, and detection of 24-hour urinary sodium excretion, flow-mediated vasodilation, erythrocytic H₂S, and plasma pro-adrenomedullin as biological markers were the new ways that were inexpensive, non-invasive, and easy to test for finding those who would be suitable for a specific drug and treatment. <italic>Conclusion:</italic> With the help of biomarkers, the therapeutic efficacy was greatly increased for children with postural tachycardia syndrome and vasovagal syncope.</p> </abstract>